{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:09:42Z","timestamp":1789182582368,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/cad.0b013e32835396d4","type":"journal-article","created":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T02:52:01Z","timestamp":1336013521000},"page":"724-730","source":"Crossref","is-referenced-by-count":6,"title":["Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies"],"prefix":"10.1097","volume":"23","author":[{"given":"Vivian E.","family":"von Gruenigen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi E.","family":"Frasure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"DeBernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Heugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-8-20210227","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R3-8-20210227","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ygyno.2004.07.035","article-title":"Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.","volume":"95","author":"Traina","year":"2001","journal-title":"Gynecol Oncol"},{"key":"R4-8-20210227","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2009.08.001","article-title":"Review role of topotecan in gynaecologicial cancer: current indications and perspectives.","volume":"74","author":"Lorusso","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"R5-8-20210227","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to therapy with oral antineoplastic agents.","volume":"94","author":"Partridge","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R6-8-20210227","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy.","volume":"15","author":"Liu","year":"1997","journal-title":"J Clin Oncol"},{"key":"R7-8-20210227","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0959-8049(97)10173-3","article-title":"Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.","volume":"34","author":"Gerrits","year":"1998","journal-title":"Eur J Cancer"},{"key":"R8-8-20210227","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.bjc.6690532","article-title":"Oral topotecan: bioavailability and effect of food co-administration.","volume":"80","author":"Herben","year":"1999","journal-title":"Br J Cancer"},{"key":"R9-8-20210227","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2001.19.19.3967","article-title":"Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.","volume":"19","author":"Clarke-Pearson","year":"2001","journal-title":"J Clin Oncol"},{"key":"R11-8-20210227","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5414\/CPP47195","article-title":"Bioequivalence study of a new oral topotecan formulation relative to the current topotecan formulation in patients with advanced solid tumors.","volume":"47","author":"Oostendorp","year":"2009","journal-title":"Int J Clin Pharm Ther"},{"key":"R12-8-20210227","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CAD.0b013e3283350092","article-title":"Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study.","volume":"21","author":"Stathoppulos","year":"2010","journal-title":"Anticancer Drugs"},{"key":"R13-8-20210227","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rational for new directions.","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"R14-8-20210227","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/pbc.22690","article-title":"A phase II study of metronomic oral topotecan for recurrent childhood brain tumors.","volume":"56","author":"Minturn","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R15-8-20210227","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ygyno.2010.11.008","article-title":"A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).","volume":"120","author":"Herzog","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R16-8-20210227","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/jnci\/94.24.1883","article-title":"Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.","volume":"94","author":"Baker","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R17-8-20210227","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/0091270009343699","article-title":"A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mgm2 administered weekly as a 30-minute intravenous infusion in patients with cancer.","volume":"50","author":"Curtis","year":"2010","journal-title":"J Clin Pharm"},{"key":"R19-8-20210227","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R20-8-20210227","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s002800000141","article-title":"Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.","volume":"46","author":"Akhtar","year":"2000","journal-title":"Cancer Chemo Pharmacol"},{"key":"R21-8-20210227","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","article-title":"Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.","volume":"20","author":"Kruijtzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"R22-8-20210227","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2174\/138920111795163913","article-title":"The challenge of exploiting ABCG2 in the clinic.","volume":"12","author":"Robey","year":"2011","journal-title":"Curr Pharmac Biotech"},{"key":"R23-8-20210227","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics - drug disposition, drug targets, and side effects.","volume":"348","author":"Evans","year":"2003","journal-title":"N Engl J Med"},{"key":"R24-8-20210227","first-page":"5938","article-title":"Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.","volume":"59","author":"Brangi","year":"1999","journal-title":"Cancer Res"},{"key":"R25-8-20210227","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1368-7646(03)00005-0","article-title":"Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.","volume":"6","author":"Sparreboom","year":"2003","journal-title":"Drug Resist Updat"},{"key":"R26-8-20210227","doi-asserted-by":"crossref","first-page":"650","DOI":"10.4161\/cbt.4.6.1731","article-title":"Effect of ABCG2 genotype on the oral bioavailability of topotecan.","volume":"4","author":"Sparreboom","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"R27-8-20210227","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1365-2710.2009.01127.x","article-title":"ABCG2 polymorphisms, 34GA and 421CA in a Korean population: analysis and a comprehensive comparison with other populations.","volume":"35","author":"Kim","year":"2010","journal-title":"J Clin Pharm Ther"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e32835396d4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:58:13Z","timestamp":1786039093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201208000-00008"}},"subtitle":["a phase I study"],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32835396d4","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}